The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Big Data, Real World, Multi-State Study Finds RSV Vaccine Highly Effective in Protecting Older Adults Against Severe Disease, Hospitalization and Death Oct. 17, 2024 — This multi-state study is ...

COVID-19 vaccination coverage has progressed unevenly throughout the world. Moreover, 1.01 and 1.43 doses for each person are ...

while some current vaccines are only modestly effective against their target germ, like the seasonal flu shot. There’s only so much time and resources that can be devoted to developing vaccines ...

the mRNA vaccines from Pfizer and Moderna — aren’t effective. Get top local stories in Southern California delivered to you ...

Let's consider two examples: Vertex Pharmaceuticals (NASDAQ: VRTX) and Moderna (NASDAQ: MRNA). Here's why these biotechs are ...

LILLE, France, Nov. 12, 2024 /PRNewswire/ -- Today Vaxinano, a biotech company headquartered in Lille (France) announced an ...

Dr. Patricia Martin, Chief Operating Officer of LimmaTech, stated, "The start of this trial is a significant milestone for the S4V2 program and our combined efforts with Valneva to bring an effective ...

New preclinical data demonstrates that CMV antigens identified with Evaxion's AI-Immunology platform trigger targeted immune responses Results also showcase the successful design of a proprietary pref ...